In June 2025, Medtronic announced inEstablishment of a Global Capability Center (GCC) for Diabetes in Pune, India, planning to invest in the next five years$50 million (approximately RMB 350 million)For the construction and expansion of the center.

The center focuses on diabetes technology innovation and operation optimization, and will create in the first yearMore than 300 service and software positions, with plans to double the workforce over the next four years.

Executive Vice President of Medtronic's Diabetes BusinessOue Dalara pointed out that India, as a global leading IT hub, has a talent pool comparable to Medtronic.“Simplify Diabetes Management” The objectives are highly aligned. In addition, the Pune GCC will also house patient financial services and global operations support functions, further unlocking India's synergistic value in the digital health sector.

The Strategic Split of Medtronic's Diabetes Business:

MiniMed Independence and Ecosystem Reconstruction

As the global insulin pump marketHolding a 70% market share (as of 2022 data), Medtronic announced in May 2025 the spin-off of its diabetes business, and recently confirmed the new company's name as “MiniMed”。

This decision aims to optimize the product portfolio by focusing on high-margin markets, while relying onThe technology heritage of the namesake brand acquired for $3.7 billion in 1996 continues MiniMed's brand recognition advantages in fields such as automated insulin delivery systems (e.g., MiniMed 780G) and smart insulin pens (InPen).

After SplittingMiniMed Plans to Complete IPO in 18 Months, will integrate the full-chain technology ecosystem of Medtronic's diabetes business after independent operation, strengthening the technical barriers of the closed-loop system and Continuous Glucose Monitoring (CGM).

The Historical Depth of India's Layout

PuneThe establishment of GCC strategically echoes the spin-off of MiniMed: the former reduces costs through localized R&D in China (R&D costs in India are 30%-50% lower than in Europe and America), while the latter accelerates technological iteration through independent operation.

Medtronic's operations in India can be traced back toIn the 1970s, in recent years it has also been continuously increasing its investment in the Indian market, and this is not the first time it has increased investment.

August 2020，Investment of 12 billion rupees (approximately 160 million US dollars) to expand the R&D center in Hyderabad, India, making it the largest engineering and innovation center outside the United States for Medtronic.

2023 YearAn additional investment of 30 billion rupees (approximately 350 million US dollars) has been made to expand its Medical Engineering and Innovation Center (MEIC) in Hyderabad, located in the southern Indian state of Telangana.

July 2024Medtronic Officially Announces Expansion of New Global IT Center in Hyderabad, India; Center to Receive $60 Million Investment Over Next Three to Five Years

FromProgressive investment from 160 million to 350 million and then to 60 million US dollars，Medtronic's layout in India has evolved from单纯的 cost optimization to"R&D - Digital - Industry"The full-chain penetration. The $50 million investment in the Pune GCC, which was implemented in less than a year, further highlights the strategic urgency to establish India as a global hub for diabetes technology.

Global Competitive Landscape:

Medtronic's Moat and Challenges

Medtronic's Market Dominance and Growth Resilience

As the absolute leader in the global insulin pump market,As ofIn 2022, Medtronic's insulin pump accounted for approximately70%Market share. Medtronic CEO Jeff·Masa previously told the media in an interview that the diabetes business is currently in good condition.Continuous double-digit growth for six consecutive quarters, and the product line is also very strong.

Public data shows that Medtronic's diabetes business has a global presence.With over 8,000 employees and operations worldwide, in the fiscal year 2025, Medtronic's diabetes business accounted for 8% of Medtronic's total revenue and 4% of Medtronic's segment operating profit. After the spin-off, Medtronic's diabetes business will be listed as an independent company. Medtronic expects that the divestiture of the diabetes business will immediately enhance profitability and improve overall margins.

Under Multi-dimensional Competitive PressureChallenge

Medtronic inThe CGM field is experiencing a dual competitive squeeze.

Abbott, DexcomInternational leading enterprises rely on their first-mover technological advantages, deeply integrating high-precision dynamic monitoring technology with insulin pumps to build a "monitoring - treatment" closed-loop ecological barrier.

AndEmerging CompetitorsThen, with localized adaptation design and cost control strategies, enter the mid-to-low-end market, promote the reconstruction of the industry price range, and penetrate grassroots healthcare.

This two-way game not only reshapes the distribution of market share but also drives the industry towards"Precision Monitoring + Intelligent Intervention"The evolution of the model has forced Medtronic to accelerate the integration of R&D resources and manufacturing advantages in emerging markets like India, seeking a breakthrough point between technological innovation and cost balance.

Panorama of Multinational Giants' Layout in India

GE, Philips, and Omron's Localization Strategies in China

In addition to Medtronic, several medical technology giants are also expanding their presence in India, creating a competitive landscape for local technology development and manufacturing.

GE Healthcare: $1 Billion Bet on AI R&D and South Asia Supply Chain

At the beginning of 2025, GE announced a $1 billion investment in the Indian market over the next five years, with the majority of the funds focusing on the research, development, and application of artificial intelligence in areas such as medical imaging and precision diagnostics.

As a joint venture between GE and India's Wipro Group, Wipro GE Healthcare has become the largest medical technology company in South Asia, with four manufacturing plants located in Bangalore (the Silicon Valley of India), covering the localized production and export of more than 30 GE products, serving markets in six South Asian countries including India and Bangladesh.

Philips: Pune Manufacturing Hub Radiates Global Imaging Market

PhilipsIn 2008, through the acquisition of India's Alpha X-ray Technology Company and Medtronic, entered the South Asian market, located inPuneThe development and manufacturing center focuses on the localization of diagnostic and interventional imaging solutions in China.

Initially targeting the Indian market, the factory has now been upgraded to a global supply hub, providing core components for CT and MRI equipment to Philips' global imaging business.

It is worth noting that Medtronic has chosenEstablishment of Global Diabetes Competency CenterThe location is alsoPune。

Omron:RMB 1.13 Billion Bet on India's Blood Pressure Monitor Market

Omron announces it will expand in southern IndiaTamil Nadu Invests INR 1.28 Billion (Approximately RMB 113 Million) to Establish Its First Medical Device Factory in the Region.

The factory, located in the Mahindra Industrial Park in Chennai, the capital of Tamil Nadu, is planned to cover an area of 6.02 acres and is expected to begin operations by March 2025. It will focus on supplying blood pressure monitors to India's domestic market. With the support of the new plant, Omron aims to achieve a sales volume of approximately 5 million units in the Indian market by 2030.

Strategic Depth: India's Triple Value as a Pivot of Globalization

Medtronic Continues to Increase Investment in India, Essentially Is a Reflection of“Talent - Policy - Cost” In-depth Layout of the Triangle Model:

• Talent Dividend：IndiaWith 20% of the global software export share (second only to the United States) and a software production capacity scale of 150 billion US dollars, occupying half of the global software outsourcing market. This advantage enables the Pune GCC's first-year planning of the AI diabetes management technology team to mainly rely on India's local talent pool.—— Bangalore alone is home to 1.2 million software engineers.

• Policy Synergy：With the help of India“Production-Linked Incentives”(PLI) plan, Medtronic can enjoy a 15%-20% tax reduction while avoiding trade barriers in the European and American markets;

• Cost Leverage：The transfer of non-core R&D and operational functions to India is expected to reduce the group's overall operating costs., releasing funds forMiniMed's Core Technology R&D.

From HyderabadFrom MEIC to Pune GCC, Medtronic's layout in India has evolved from single-point R&D to ecosystem collaboration. With the spin-off of MiniMed and the establishment of the GCC, this medical giant is attempting to use India as a fulcrum to reconstruct the global competitiveness of its diabetes business.

For Medtronic"Developed in India+ Global CommercializationWhat do you think is the biggest potential risk of this model? How will the trend of multinational medical giants betting on India reshape the global medical technology industry map?Feel free to share your thoughts in the comment section!